3SBio (STU:83B) Dividend-Payout-to-FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:83B 3SBio Inc STU:83B
82 GF Score
Price €1.84
GF Value €1.24
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is 3SBio Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.

STU:83B
82GF Score
3SBio Inc STU:83B
Dividend-Payout-to-FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is 3SBio (STU:83B) Overvalued in 2026?

Based on GuruFocus' analysis, 3SBio stock appears to be overvalued. The current stock price of €1.84 is trading 48.7% above its estimated GF Value™ of €1.24. GuruFocus considers 3SBio to be Significantly Overvalued.

Key valuation signals for STU:83B:

  • Dividend-Payout-to-FFO:
  • GF Value™: €1.24 vs. price of €1.84 (48.7% above fair value)
  • GF Score™: 82/100 with 1 warning sign

No single metric tells the full story. See the STU:83B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

3SBio Business Description

Other Exchanges TRSBF:USA01530:Hong Kong
Address No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN
3SBio Inc. is a China-based biopharmaceutical company engaged in the development, production, marketing, and sale of biopharmaceutical and small-molecule products. Its core commercialized drugs include TPIAO (recombinant human thrombopoietin), the recombinant human erythropoietin products EPIAO and SEPO, the TNF inhibitor Yisaipu, and Cipterbin (trastuzumab biosimilar). The company also markets the Mandi series of minoxidil products for hair loss. 3SBio focuses primarily on nephrology, oncology, autoimmune diseases, and dermatology, selling mainly to hospitals and medical institutions across China. It operates through a direct sales force and distributor network, generating revenue from product sales. The company has expanded through subsidiaries and acquisitions, including a stake in Akeso and the dermatology-focused business of its subsidiary, and it maintains research and manufacturing operations in China with some international presence.
82GF Score

Get the complete analysis for STU:83B

Dividend-Payout-to-FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.84
Price
€1.24
GF Value